A common chemotherapy agent might be made more effective through supplements of histidine, suggests a mouse study published online this week in Nature.
Methotrexate is a chemotherapy agent used to treat various solid tumours and blood cancers. An antimetabolite, it works by stopping cancer cells from both making and repairing DNA, as well as producing proteins, both of which are extensively required for cancer growth. Methotrexate works by inhibiting the production of tetrahydrofolate (THF), which is essential to nucleotide synthesis. Methotrexate’s drawback, however, is its high toxicity, which limits its use in patients. Means of enhancing methotrexate’s effect on cancer cells are therefore highly sought after.
David Sabatini and colleagues used a CRISPR-Cas9-based screen of methotrexate-treated leukaemia cells to pick out genes that increase sensitivity to the chemotherapy agent. Through this, they identified a process that had not previously been linked to methotrexate sensitivity: the encoding of an enzyme that helps catabolize histidine, an amino acid used to synthesize proteins. As with methotrexate, the process of catabolizing histidine also reduces THF levels in cells - albeit by draining them, rather than by inhibiting THF production - thereby enhancing the negative impact of the chemotherapy agent.
In mice, chemotherapy treatments with low doses of methotrexate were seen to be more effective at reducing tumour size and killing tumour cells when also administered with histidine. If these findings translate to clinical trials, the authors conclude, the effectiveness of methotrexate-based treatments could be improved with simple and inexpensive dietary interventions, allowing doctors to prescribe lower doses of the toxic agent.
Environment: Value of national parks’ impact on mental health estimatedNature Communications
Nature Reviews Endocrinology: A new approach for assessing health risks of endocrine disruptorsNature Reviews Endocrinology
Neuroscience: A brain-scanning bike helmetNature Communications